Novo Nordisk posts third-quarter 2026 results
CEO Mike Doustdar comments on the figures, with further detail set out in the company announcement.
Latest Novo Nordisk News & Updates
See the latest news and media coverage for Novo Nordisk. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global pharmaceutical company developing treatments for chronic diseases
novonordisk.com- Headquarters
- Bagsværd, Denmark
- Founded year
- 1923
- Company type
- Public company
- Number of employees
- 61,000+
- Industry
- Pharmaceuticals
Last updated
Latest news about Novo Nordisk
In short: Novo Nordisk raised its outlook as Wegovy pill sales beat estimates and delayed CagriSema’s European launch.
Company announcements
Novo Nordisk raises full-year outlook on continued GLP-1 momentum
Adjusted operating profit rises 27% at CER to DKK 31,720 million, while reported operating profit falls 9% on DKK 8.7 billion impairment charges.
Novo Nordisk announces menopause weight loss data
Phase 3 trials show a 25% average weight loss across all stages, offering women meaningful health benefits.
Novo Nordisk delays denecimig US approval due to facility issues
FDA extends review for manufacturing remediation without citing data deficiencies, targeting a first half 2027 launch date.
Media coverage
Novo Nordisk's CFO Karsten Munk Knudsen to leave company
Novo Nordisk said on Wednesday its Chief Financial Officer Karsten Munk Knudsen would step down and that Luigi La Corte would join as its new...
Novo Boosts Forecast as Wegovy Pill Beats Estimates
Novo Nordisk A/S boosted its forecast for the year, citing sales of its Wegovy weight-loss pill as it continues to fight for a larger share...
Novo Nordisk's Q2 Surge: Why Q3 Remains a Blind Spot
Novo Nordisk reported $78.49B revenue and $20.99B net income in Q2 2026, driven by strong demand for core therapies.
Novo enters into a licensing agreement with Chinese giant regarding new potential tablet treatment
Novo has entered into a licensing agreement with the Chinese pharmaceutical giant Jiangsu Hengrui Pharmaceutical for a GLP1R/GIPR agonist in phase 1.
Never miss news about Novo Nordisk
Track Novo Nordisk and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Novo Nordisk competitors & trending companies
Browse news for competitors to Novo Nordisk and other trending companies.